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Abstract
Background: Patients with Phenylketonuria (PKU) are exposed to multiple cardiovascular risk factors, but the
clinical significance of these abnormalities is yet unknown. The purpose of this study was to characterize the
cardiovascular phenotype in adult patients with PKU by clinical and dietary data, measurements of biochemical
markers, and non-invasive examination of vascular functions.
Results: Twenty-three adult patients with PKU (age: 18–47 y; 30.8 ± 8.4 y) and 28 healthy controls (age: 18–47 y;
30.1 ± 9.1 y) were included in this study. PKU patients had significantly higher systolic and diastolic blood pressure,
increased resting heart rate and a higher body mass index. Total cholesterol and non-HDL cholesterol levels were
significantly increased in PKU patients, whereas plasma levels of HDL cholesterol and its subfraction HDL2 (but not
HDL3) were significantly decreased. The inflammatory markers C-reactive protein and serum amyloid A protein and
the serum oxidative stress marker malondialdehyde were significantly higher in patients with PKU. Venous occlusion
plethysmography showed marked reduction in post-ischemic blood flow and the carotid to femoral pulse wave
velocity was significantly increased demonstrating endothelial dysfunction and increased vascular stiffness.
Conclusions: This study shows that the cardiovascular phenotype of adult PKU patients is characterized by an
accumulation of traditional cardiovascular risk factors, high levels of inflammatory and oxidative stress markers,
endothelial dysfunction and vascular stiffness. These data indicate the need for early cardiovascular risk reduction in
patients with PKU.
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Background
Phenylketonuria (PKU) is an autosomal-recessive inborn
error of phenylalanine (Phe) metabolism, caused by the
deficiency of the enzyme phenylalanine hydroxylase
(PAH). In untreated patients, the accumulation of Phe
and its metabolites leads to mental retardation and other
neurological symptoms [1]. The objective of PKU-treat-
ment is to lower Phe blood concentrations in order to
prevent these symptoms. Thus, early diagnosis, usually
via newborn screening, and immediate initiation of a
strict, life-long low-phenylalanine diet is recommended
[1–3]. This diet consists of a low natural protein intake
supplemented with a synthetic Phe-free amino acid for-
mula [1].
Previous studies have shown a high prevalence of car-
diovascular risk factors in young patients with PKU.
Among the traditional risk factors, dyslipidemia, obesity,
and hypertension are the most prevalent [4–7]. More-
over, oxidative stress, hyperhomocysteinemia and pro-
teinuria [5, 6, 8] have been reported in PKU patients and
may further increase their susceptibility for cardiovascu-
lar complications [8–10]. Adult patients with low adher-
ence to the Phe-free diet and therefore high Phe plasma
concentrations seem to have higher levels of various car-
diovascular risk factors [7, 8, 11]. Thus, PKU patients
are exposed to multiple cardiovascular risk factors, but
their impact on vascular disease is currently unknown.
The purpose of this study was to further characterize
the cardiovascular phenotype in adult patients with
PKU by clinical and dietary data, measurements of
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biochemical markers, and non-invasive examination of
vascular functions. Venous occlusion plethysmography
(VOP) was used to evaluate endothelial function, and
the carotid to femoral pulse wave velocity (PWV) to as-
sess the arterial stiffness.
We hypothesized that these measurements might de-
tect distinct vascular alterations already in early adult-
hood and, together with clinical data and selected
biochemical markers, improve the cardiovascular risk as-
sessment of PKU patients.
Methods
Study population
Early diagnosed patients with PKU aged 18 years and
older who were on a lifelong Phe-restricted diet with
synthetic amino acid supplementation were eligible for
the study. Exclusion criteria were inability to cooperate
with study requirements, acute infections, smoking and
pregnancy. All examinations were performed on the
same day and consisted of a standardized interview,
measurements of weight, height, resting heart rate, blood
pressure, blood drawing (after an overnight fast), meas-
urement of vascular stiffness by PWV and endothelial
function by VOP.
The patient’s daily natural protein intake was esti-
mated by review of the regularly conducted three-day-
dietary-protocols. Total daily protein intake was defined
as the sum of synthetic protein and natural protein
intake.
Biochemical analyses
All analyses were performed on venous blood samples
taken under fasting conditions. Phe and tyrosine concen-
trations in plasma were determined by amino acid
analyzer. Renal function was assessed by the estimated
glomerular filtration rate (eGFR) based on the CKD-EPI
equation [12].
For all other parameters, serum aliquots were frozen
at − 80 °C until analysis. Serum concentrations of total
cholesterol, HDL cholesterol (HDLc) and LDL choles-
terol (LDLc) were measured using commercially avail-
able assay kits (Diasys, Holzheim, Germany), a
microtiter plate and a spectral photometer device (Skan
IT software, version 2.4.4, Thermo Scientific, Langensel-
bold, Germany). To obtain the HDL2c/3c ratio, the
HDL3c fraction of the serum was precipitated using the
Quantolip reagent B (Technoclone, Wien, Austria) and
HDL2c was calculated. Serum amyloid A (SAA), C-re-
active protein (CRP), apolipoprotein A1 (apoA1) and
myeloperoxidase (MPO) were determined using the
Luminex™ technique with commercially available assay
kits (Merck Millipore, Darmstadt, Germany) and mea-
surements were performed on a Bio-Plex® device with
Bio-Plex® software (version 6.1) (Biorad, München,
Germany). Malondialdehyde (MDA) and 3-nitrotyrosine
(3-NT) were determined in serum by colorimetric-based
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s protocol (Cloud-Clone Corp.,
Houston, TX, USA).
The urine protein-to-creatinine ratio was measured in
all patients by immunoturbidimetry.
Vascular studies
Blood pressure and resting heart rate were measured
with a Dinamap® Pro 100 V2 patient monitor after 10
min of rest in supine position. The mean values of two
measurements were used.
Venous occlusion plethysmography was performed
with the Compactus device (Sogut Medical, Königsdorf,
Germany) as previously described [13]. Patients were su-
pine for at least 10 min prior to the examination, ankles
and legs were positioned on foam blocks above heart
level. Blood flow measurements were performed on both
lower legs using a strain gauge, detecting volume differ-
ences, while pneumatic occlusion cuffs connected to the
Compactus device temporarily interrupted the blood
flow on the upper legs. Measurement of the leg baseline
blood flow (LBF in ml blood/100ml leg volume /min)
was performed by inflating the cuffs to 60 mmHg for 5 s
and thereby occluding the venous blood flow. The aver-
age of 6–9 recordings was used for the analysis. To
measure the post-ischemic blood flow, 3 min of ischemia
were induced by inflating the cuffs to 180mmHg or 50
mmHg above the systolic blood pressure. The subse-
quent blood flow was measured after deflation. Five mea-
surements were performed by inflating the cuffs to 60
mmHg for 5 s every 10 s. The post-ischemic peak flow
(PIPF in ml/min) was defined as the maximum flow
within 15 s after ischemia. The post-ischemic flow reserve
(PIFR) was defined as the ratio between PIPF and LBF.
Arterial stiffness was assessed by measuring the carotid
to femoral PWV, which is considered the gold standard
for this purpose and recommended by current guidelines
[14, 15]. Patients were supine for at least 10 min prior to
the examination. The transit time of the pulse waves be-
tween the right carotid artery and the right femoral ar-
tery was measured using the Vicorder device (SMT
Medical, Würzburg, Germany). The carotid to femoral
path length was calculated by subtracting the distance
between the carotid recording site to the suprasternal
notch from the distance between the femoral record-
ing site via the umbilicus to the suprasternal notch
[16]. Distances were determined using a measuring
tape. The PWV was calculated by the Vicorder as ca-
rotid to femoral path length (m) divided by the tran-
sit time of the pulse wave (s). We used the mean
PWV out of 3 to 5 measurements.
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Statistical analysis
A priori sample size estimates were calculated with a
power analysis based on the results of a previous clinical
study, which showed that the PWV was significantly
higher in patients after renal transplantation compared
to controls [17], assuming that in PKU increased arterial
stiffness might be due to a renal dysfunction [5].
With a power of 80% and considering 30% more con-
trols than patients for a better comparison, the calcu-
lated sample size was n = 21 for PKU patients and
n = 28 for healthy controls. We used Tukey’s method
to exclude outliers [18].
Statistical analyses were performed using IBM SPSS
(Windows, Version 24). For non-parametric distribution,
data are expressed as median and interquartile range. In
these cases, the Mann-Whitney-U-test was used for stat-
istical comparison between the groups and the Spear-
man-Rho correlation coefficient to explore associations
with other variables. For parametric distribution, data
are expressed as mean ± standard deviation, and the in-
dependent t-test and Pearson correlation coefficient
were used for statistical analysis. Multiple linear regres-
sion analysis was used to evaluate the influence of mea-
sured variables to the outcome variable of interest. A
value of p < 0.05 was considered significant.
Results
Patient characteristics
Of 123 patients regularly attending the outpatient clinic
for metabolic disorders at the Charité-Universitätsmedi-
zin Berlin, 29 patients who met the inclusion criteria
and gave informed consent were enrolled in the study. 3
patients were excluded after review of their clinical his-
tory (patients were smokers) and 3 patients did not
complete the study as they had to leave before comple-
tion of the investigation. Thus, a total of 23 patients with
PKU and 28 healthy controls were included in the final
analysis. 19 patients were classified as classical PKU and
4 patients mild PKU. 5 patients were regularly taking
anti-hypertensive medication (4 patients monotherapy,
one patient combination therapy) and one patient was
on statin therapy.
The demographic and clinical characteristics of both
groups are shown in Table 1. Complete clinical charac-
teristics were collected only in 21 patients. Two patients
refused physical examination but participated in the vas-
cular studies. Age was similar in both groups (PKU pa-
tients: 30.8 ± 8.4 y, controls: 30.1 ± 9.1 y) ranging from
18 to 47 years. BMI, resting heart rate and the systolic
blood pressure were significantly higher in PKU patients
than in healthy controls.
Renal function was normal in PKU patients (n = 22) as
assessed by the serum creatinine (0.78 ± 0.13 mg/dl),
urea levels (22.5 ± 5.2 mg/dl), eGFR (113.9 ± 13.2 ml/
min/1.73 m2) and the urine protein-to-creatinine ratio
(77.2 ± 17.4 mg/g, n = 16; normal: < 140 mg/g).
Body mass index
PKU patients had a mean BMI of 27.6 ± 5.4 kg/m2,
which is classified as preobese according to the WHO
criteria [19]; 48% of the patients had a weight within the
normal range, 19% were preobese and 33% were obese
(50% of female and 18% of male patients). BMI was sig-
nificantly higher compared to healthy controls with a
mean BMI in the normal range (mean: 23.4 ± 6.4 kg/m2).
The presence of a higher BMI and higher blood pres-
sure raised the question whether these were components
of a metabolic syndrome, which is known to be associ-
ated with increased arterial stiffness and higher inflam-
mation [20, 21]. We therefore analyzed the fasting
plasma glucose in all patients (mean: 84.7 ± 8.1 mg/dl)
and reviewed triglyceride levels, HDLc levels and blood
pressure, as part of the definition of metabolic syndrome
following the National Cholesterol Education Program’s
Adult Treatment Panel III report (ATP III) [22]. Only 2
patients fulfilled 2 out of 5 criteria for metabolic syn-
drome, while 3 positive criteria are necessary for the
diagnosis. However, as we did not measure the waist cir-
cumference, the diagnosis could not be made. The
remaining 21 patients did not meet the criteria of a
Table 1 Clinical characteristics of patients and healthy controls
Characteristics PKU patients Control group p-value
mean ± SD n mean ± SD n
Male sex - n (%) 13 (57) 11 (39)
Age - years 30.8 ± 8.4 23 30.1 ± 9.1 28 n.s.
BMI - kg/m2 27.6 ± 5.4 21 23.4 ± 6.4 28 < 0.001
Heart rate - bpm 72.8 ± 10.5 21 62.1 ± 9.9 27 0.001
Mean arterial pressure - mmHg 89.9 ± 7.5 21 84.5 ± 7.1 28 0.014
Systolic blood pressure - mmHg 124.6 ± 10.4 21 116.1 ± 10.7 28 0.012
Diastolic blood pressure -mmHg 72.5 ± 6.9 21 68.6 ± 7.3 28 0.023
Pulse pressure - mmHg 52.1 ± 7.1 21 47.5 ± 10.1 28 n.s.
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metabolic syndrome. However, there was an inverse cor-
relation of HDLc levels with the systolic blood pressure
(r = − 0.439, p = 0.047), indicating an association of these
metabolic syndrome components.
Dietary protein and Phe plasma concentrations
Current Phe plasma concentrations, mean blood Phe
plasma concentrations of the previous 5 years (Phe mean
5 y), tyrosine plasma concentrations and protein intake
of the PKU patients are shown in Table 2. We calculated
total protein and current synthetic protein intake
(58.1 ± 14.2 g/d, 72.8 ± 12.4 g/d) and the mean of the
synthetic and total protein intake of the last 5 years per
kilogram body weight (0.75 ± 0.22 g/kg/d, 0.94 ± 0.21 g/
kg/d). There were no significant associations between
dietary intake parameters (Table 2) and vascular mea-
surements, inflammatory or oxidative stress markers and
serum lipoproteins.
Phe plasma levels significantly and positively corre-
lated with the BMI (r = 0.689, p = 0.001) and the concen-
tration of non-HDLc (r = 0.547, p = 0.010), triglyceride
(r = 0.452, p = 0.040), and the LDLc/HDLc-Ratio (r =
0.614, p = 0.003), respectively and negatively with the
HDL2c concentration (r = − 0.484, p = 0.026) and the
HDL2c/3c-ratio (r = − 0.497, p = 0.022).
Patients with poorly controlled PKU,defined as current
Phe concentration higher than 1200 μmol/l, according to
the German PKU recommendations [23], had higher
serum lipid levels and a higher BMI, but there was no
significant difference in other blood parameters and the
vascular measurements (Table 3). Phe plasma concentra-
tions did not correlate with biomarkers of oxidative
stress or inflammation or with vascular measurements.
Lipoprotein profile
Table 4 shows the serum levels of total lipids, lipopro-
tein lipids and apolipoproteins. PKU patients had signifi-
cantly lower HDLc, lower HDL2c and higher non-HDLc
levels, altogether indicating an atherogenic pattern [24,
25]. The non-HDLc levels (r = 0.486, p = 0.026), but no
other blood lipid levels were significantly associated with
the BMI.
The HDL2c levels were negatively correlated with the
systolic blood pressure (r = − 0.470, p = 0.031, n = 21),
Phe plasma concentrations (r = − 0.484, p = 0.026) and
MDA (r = − 0.580, p = 0.004) and positively with SAA
(r = 0.517, p = 0.014, n = 22) in PKU patients. This sug-
gests associations of the altered cholesterol content
within the HDL fractions with dietary adherence, inflam-
mation and oxidative stress.
Inflammation and oxidative stress
As further atherogenic risk factors, we investigated
serum biomarkers for inflammation, SAA and CRP, and
oxidative stress, MDA, MPO, 3-NT (Table 4, Fig. 1).
Both SAA and CRP serum concentrations were elevated
2–3-fold in PKU patients compared to controls and were
significantly correlated with the BMI (CRP: r = 0.426,
p = 0.003; SAA: r = 0.322, p = 0.027), suggesting an influ-
ence of the increased weight on the patient’s inflamma-
tory status.
Similarly, MDA levels were significantly higher in PKU
patients, but there were no significant differences of
MPO and 3-NT levels between the groups.
We further analyzed serum selenium concentrations
as part of the antioxidatively acting glutathione peroxid-
ase, which were found to be negatively correlated with
elevated MDA levels in other studies [26, 27]. However,
selenium levels were in a normal range (0.84 ±
0.18 μmol/l) and there was no correlation with MDA
levels.
Taken together, these data indicate the presence of in-
flammation and oxidative stress in the PKU patients.
Vascular studies
Endothelial dysfunction was evident in the PKU patients,
who had a significantly lower PIFR than the healthy con-
trols (9.3 ± 4.9 versus 14.1 ± 5.5, p = 0.005; Fig. 2). Endo-
thelial function was also inversely associated with the
BMI (r = − 0.50, p = 0.028), but not with systolic or dia-
stolic blood pressure in the PKU patients. A multiple re-
gression analysis was performed to test whether the
observed differences in endothelial function between the
groups were independently affected by the BMI. Only
the BMI (but not the diagnosis of PKU) was a significant
predictor of PIFR (β = − 0.50 p = 0.002, R2 = 0.32), sug-
gesting that endothelial dysfunction in the PKU patients
was mediated by their increased BMI. In some patients
and controls, no reliable vascular measurements could
be performed.
Arterial stiffness was significantly increased in PKU
patients compared to controls, as indicated by the
PWV (6.4 ± 1.7 m/s versus 5.1 ± 0.8 m/s, p = 0,001;
Table 2 Plasma amino acid levels and dietary intake in PKU
patients
mean ± SD n
Phenylalanine – μmol/l 1172 ± 380 21
Tyrosine – μmol/l 85.6 ± 38.5 21
Phe mean 5y – μmol/l 1027 ± 263 22
Current total protein intake - g/d 72.8 ± 12.4 19
Current synthetic protein intake - g/d 58.1 ± 14.2 19
Current total protein intake - g/kg/d 0.92 ± 0.20 18
Current synthetic protein intake - g/kg/d 0.73 ± 0.21 18
Total protein intake mean of 5y - g/kg/d 0.94 ± 0.21 18
Synthetic protein intake mean of 5y - g/kg/d 0.75 ± 0.22 18
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Fig. 2). As expected, PWV correlated with age (r =
0.756, p < 0.001), but there was no correlation with
the systolic blood pressure or the BMI. A multiple
regression analysis (R2 = 0.49) showed that both, age
(β = 0.55, p < 0.001), and the diagnosis of PKU (β = −
0.48, p < 0.001) were independent predictors of the
PWV.
Altogether, these vascular studies showed endothelial
dysfunction and an increased arterial stiffness in patients
with PKU, representing subclinical disturbances in both
vascular function and structure.
Discussion
This study confirms the presence of classical risk factors
for cardiovascular disease in adult patients with PKU, in-
cluding an increased blood pressure, obesity and an
atherogenic lipoprotein profile. In addition, we found an
increase in resting heart rate, elevated biochemical
Table 3 Significantly different clinical and laboratory parameters of well * (Phe < 1200 μmol/l; n = 13) and poorly (Phe > 1200 μmol/l;
n = 8) controlled patients
Well controlled patients Poorly controlled patients
mean ± SD mean ± SD p-value
Phe μmol/l 920.2 ± 163.4 1580.0 ± 254.3 < 0.001
Phe mean 5y - μmol/l 829.3 ± 139.2 1247.0 ± 163.4 < 0.001
Total protein intake mean of 5y - g/kg/d 1.0 ± 0.2 0.7 ± 0.0 0.022
Age - years 28.3 ± 8.7 35.3 ± 6.9 0.050
BMI - kg/m2 24.0 ± 2.3 32.1 ± 5.3 0.001
LDLc/HDLc 1.9 ± 0.5 2.3 ± 0.5 0.025
Triglycerides - mmol/l 1.0 ± 0.4 1.9 ± 1.1 0.005
Non-HDLc - mmol/l 2.7 ± 0.4 3.2 ± 0.3 0.017
HDL2c - mmol/l 0.7 ± 0.3 0.5 ± 0.2 n.s.
HDL2c/HDL3c 0.9 ± 0.3 0.6 ± 0.3 n.s.
*according to the German PKU recommendations [23]
Table 4 Lipoproteins, markers of inflammation and oxidative stress in patients and healthy controls
PKU patients Control group p-value
mean ± SD or median [IQR] n mean ± SD or median [IQR] n
Lipids and Lipoproteins (mmol/l)
Total Cholesterol 4.3 ± 0.6 23 3.8 ± 0.6 28 0.003
LDLc 2.8 ± 0.7 23 2.6 ± 0.8 28 n.s.
HDLc 1.4 ± 0.3 23 1.6 ± 0.3 28 0.032
LDLc/HDLc 2.1 ± 0.5 23 1.7 ± 0.6 28 0.018
ApoA1 (mg/ml) 2.1 ± 0.7 23 1.8 ± 0.3 16 n.s.
HDL2c 0.6 ± 0.3 23 0.8 ± 0.2 28 0.009
HDL3c 0.8 ± 0.1 23 0.8 ± 0.1 28 n.s.
HDL2c/HDL3c 0.8 ± 0.3 23 1.1 ± 0.3 28 0.005
Non-HDLc 2.9 ± 0.4 23 2.2 ± 0.6 28 < 0.001
Triglycerides 1.3 ± 0.8 23 1.1 ± 0.6 28 n.s.
Phospholipids 2.7 ± 0.6 23 2.6 ± 0.4 28 n.s.
Markers of Inflammation (mg/l)
SAA 6.7 [2.8–14.4] 22 2.9 [1.5–5.2] 27 0.010
CRP 18.4 [7.3–83.3] 22 6.3 [2.0–42.1] 27 0.010
Markers of Oxidative Stress
MDA (μg/ml) 0.33 [0.23–0.59] 23 0.23 [0.12–0.38] 27 0.027
MPO (μg/ml) 0.68 [0.29–0.97] 19 0.89 [0.34–1.3] 26 n.s.
3-NT (nmol/l) 1.8 [0.34–2.7] 22 1.7 [0.92–2.4] 28 n.s.
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indicators of inflammation and oxidative stress, marked
endothelial dysfunction and increased vascular stiffness.
Risk factors and biochemical markers (LDLc/HDLc,
triglycerides, non-HDLc, HDL2c) were in part modi-
fied by dietary adherence as indicated by the current
plasma Phe concentrations. These data further define
the cardiovascular phenotype of adult PKU patients
and suggest an important pathophysiological role for
dietary adherence.
The patients in this study had higher Phe plasma con-
centrations than recommended in the European guide-
lines [28] and also compared to other studies [4, 6].
Indeed, poor adherence to the strict PKU diet and
consequently high Phe concentrations are a well-known
problem in patients with PKU [28]. In a recent
multicenter survey, most patients achieved Phe blood
concentrations < 1200 μmol/l, although there was limited
consensus regarding target Phe levels for adult PKU pa-
tients [29]. The majority of surveyed adult patients in
another multicenter study admitted poor compliance
with the Phe-restricted diet, which seems to reflect
worsening of metabolic control with age reported in sev-
eral studies [30]. Thus, the rather high Phe plasma con-
centrations in our study patients most likely indicate
poor compliance with dietary advice. However, Phe
plasma concentrations in our study were not associated
with cardiovascular measurements, including systolic or
diastolic blood pressure, resting heart rate, endothelial
function and PWV.
Our patient’s characteristics were comparable with
other studies of adult PKU patients, not only including
increased Phe plasma concentrations but also
Fig. 1 a Serum lipoprotein lipids in patients with phenylketonuria (PKU) and healthy controls. Bar charts showing the mean and SD. *p < 0.05,
**p≤ 0.01, ***p≤ 0.001 (Unpaired T-Test). b Box-plot presentation of SAA, CRP and MDA serum levels in patients with phenylketonuria (PKU) and
healthy controls. *p < 0.05, **p≤ 0.01 (Mann-Whitney-U-Test)
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concerning dietary data and a high BMI [4, 29, 31]. In
our patients, the total protein intake, intake of synthetic
protein and the BMI (i.e. 27.6 kg/m2) were almost identi-
cal to adult PKU patients included in a recent study of
body composition of PKU patients in the US [31] . In
another large study of 236 British adult PKU patients, a
similar mean BMI (26 kg/m2) was reported, which in-
creased with age and was significantly correlated with
the Phe level [4]. In our study, the BMI was associated
with Phe plasma concentrations, confirming previous
studies in adult PKU patients, while such association
was not found in children with PKU [6]. Furthermore,
the BMI was associated with inflammatory markers
(CRP, SAA) and non-HDLc levels; it correlated with
endothelial dysfunction, but not with other cardiovascu-
lar measurements (blood pressure, resting heart rate and
PWV). This is in contrast to the well-known association
of BMI with systolic and diastolic blood pressure in the
general population [32].
Our study confirms several previous reports of a high
prevalence of obesity in the adult PKU population [4,
11, 33], with 52% of the patients preobese or obese. In
contrast, Rocha et al. found a much lower mean BMI
(20.1 kg/m2) and no evidence of obesity in their study of
body composition of 89 patients [34]; however, the ma-
jority of their patients was much younger (mean age
14.4 years) and had milder forms of PKU.
We found significantly higher systolic and diastolic
blood pressure as well as a significantly increased
resting heart rate. While some studies in children
and young adults with PKU found normal or even
lower blood pressure compared to controls [11, 35],
a significantly higher blood pressure was found in
obese PKU children [7] and in a study of renal func-
tion in adolescents and young adults [5]. To our
knowledge an increased resting heart rate, a pre-
dictor of cardiovascular mortality in the general
population [36], has not been described before in
PKU patients.
The lipoprotein profile in PKU patients was signifi-
cantly different from the control group. Patients had
higher levels of total cholesterol and non-HDLc and a
higher LDLc/HDLc ratio, while HDLc levels were lower.
This pattern is widely used for the definition of dyslipid-
emia and generally indicates a higher risk for cardiovas-
cular disease [37]. Importantly, the (elevated) non-HDLc
lipid fraction, but not the (decreased) HDLc, was posi-
tively associated with the BMI, which is at variance with
the most common finding in the general population,
which typically shows strong correlations between obes-
ity and (elevated) triglyceride levels and (decreased)
HDLc [38]. Instead, the low HDLc levels were inversely
associated with inflammation parameters and with Phe
plasma levels in our patients; this seems to indicate com-
plex influences on the lipoprotein profile in adult PKU
patients.
Previous studies of total cholesterol levels in PKU pa-
tients have shown inconsistent results. While in some
studies lower cholesterol levels were measured [9, 39],
we and others found higher cholesterol levels in PKU
patients [40]. Lower HDLc levels have been described
before in children and adults with PKU [6, 41].
Fig. 2 Post-ischemic flow reserve (PIFR) and pulse wave velocity (PWV) in patients with phenylketonuria (PKU) and healthy controls. Bar charts
showing the mean and SD. **p≤ 0.01, ***p≤ 0.001 (Unpaired t-test)
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The PKU diet in adults is similar to a vegetarian diet,
avoiding protein mainly of animal origin, and supple-
mented by a synthetic Phe-free amino acid mixture [39].
Patients have a low natural protein intake, a low fat in-
take and a high carbohydrate intake [39]. A vegetarian
diet is beneficial for cardiovascular health [42] and asso-
ciated with decreased levels of total cholesterol, LDLc
and HDLc [43]. Therefore, the low HDLc and HDL2c
levels in our patients could be attributed at least in part
to the PKU diet and in this context, the low HDLc levels
and the elevated LDLc/HDLc ratio may not be inter-
preted as a classical cardiovascular risk factor [39]. How-
ever, the negative associations of HDLc and HDL2c with
Phe plasma levels and MDA levels indicate that HDLc
lipid parameters were independently influenced not only
by dietary non-adherence (higher Phe plasma concentra-
tions) but also by higher oxidative stress.
HDL is a lipoprotein which has been shown to be in-
versely correlated to the risk of cardiovascular disease
[44]. Its antiatherogenic capacity derives mainly from its
function to promote cholesterol efflux from cells (i.e.
lipid laden macrophages) [45].
HDL ameliorates endothelial functions and has anti-
inflammatory properties. It can be classified into sub-
types differing in density [46]. HDL2c has been sug-
gested a more adequate risk indicator for cardiovascular
disease in the general population than HDLc and HDL3c
[24], although other studies could not confirm an associ-
ation of CVD with HDL subclasses [47]. HDL subtypes
have not been studied previously in PKU patients. We
found that the decrease in HDLc was due to low choles-
terol levels in the HDL2, but not the HDL3 fraction.
Studies analyzing the HDL subtypes in vegetarian popu-
lations also found a decrease in the HDL2 fraction,
probably due to lower cholesterol intake and a higher
polyunsaturated-to-saturated fat ratio [48]. Thus, low
HDLc and HDL2c levels in our patients were negatively
correlated with Phe plasma levels, suggesting that a low
adherence to the PKU diet with high Phe plasma con-
centrations lowered cholesterol content of the HDL2
fraction. We found an inverse correlation between MDA
and HDLc as well as HDL2c in patients with PKU.
MDA has been supposed to alter the HDL mediated
cholesterol efflux by modifying Apo A1 and can thereby
lead to dysfunctional HDL [49].
Oxidative stress as well as high SAA can alter the anti-
atherogenic properties of HDL [45, 50]. Importantly,
HDL may acquire pro-inflammatory functions by enrich-
ment with SAA [50]. We observed a strong positive cor-
relation between HDLc and SAA suggesting an
enrichment of SAA in HDL, which could possibly indi-
cate an altered function of HDL in PKU patients.
Beside the traditional cardiovascular risk markers, we
further analyzed oxidative stress and inflammation in
PKU patients as possible mediators of endothelial dys-
function and vascular stiffness. Biomarkers included
MDA, a marker of lipid peroxidation, the peroxidase
MPO, and 3-NT, reflecting tyrosine oxidation by react-
ive nitrogen species. We found that MDA-levels, but not
MPO or 3-NT, were increased in patients with PKU.
This supports the results of Ercal et al. [51], who found
increased MDA levels in a PKU animal model. Further-
more Wilke et al. [27] found higher MDA levels in chil-
dren with PKU, which were reversible after selenium
substitution. Selenium, as part of the antioxidatively act-
ing glutathione peroxidase, was found to be reduced in
PKU patients [26]. However, our patients had normal
selenium levels, indicating the presence of increased oxi-
dative stress independent of the serum selenium status.
These data support previous studies demonstrating oxi-
dative stress in patients with PKU [8, 41]. The under-
lying causes of increased oxidative stress in PKU are still
a matter of debate, but increased Phe plasma concentra-
tions have been found associated with several markers of
oxidative stress in other studies [52, 53]. Possible mecha-
nisms proposed for oxidative stress in patients with PKU
include the high blood concentrations of phenylalanine,
which may directly induce oxidative damage but also a
decreased antioxidative defense as result of the strict diet
leading to a lack of macro- and micronutrients with an-
tioxidative functions [8, 54].
While oxidative stress is well documented in PKU pa-
tients, suggesting a high pro-inflammatory potential,
markers of inflammation have been rarely studied thus
far. Deon et al., could demonstrate increased serum
levels of IL-1b, IL-6 and IL-10 in a study of 7 well-con-
trolled adolescent patients with PKU compared to con-
trols [10]. In our study, CRP and SAA in serum were
elevated and associated with the BMI, but not with Phe
levels. It is very well established that SAA plays a rele-
vant role for HDL-functionality, endothelial dysfunction
and progression of atherosclerosis [55]. In addition,
there was a significant correlation between a higher total
protein intake and lower CRP, suggesting a suppressive
effect of dietary adherence on inflammation. Altogether
these data indicate an obesity-induced inflammatory sta-
tus in the patients included in our study.
We further analyzed the vascular status and found al-
terations in its function and structure.
To our knowledge, endothelial function has not been
studied previously in patients with PKU. We here show
a significant reduction of post-ischemic blood flow in
these patients as measured by venous occlusion plethys-
mography, a long established and validated method [56].
The post-ischemic flow reserve (PIFR) was reduced by
34%, indicating striking endothelial dysfunction, which
was associated with the BMI, as shown in the multivari-
ate analysis. Obesity is a well-known cause of endothelial
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dysfunction, mainly mediated by inflammation and oxi-
dative stress [57].
A decline of the elastic properties of the aorta is a re-
sult of vascular ageing and leads to an acceleration of
the pulse wave. Thus, a high PWV can be interpreted as
a sign of relevant arterial damage. The development of
vascular stiffness in the general population is strongly
promoted by hypertension, inflammation and oxidative
stress [58], but it is unknown whether PKU itself or diet-
ary treatment of PKU may affect arterial properties by
specific metabolic mechanisms. In a small study of vege-
tarian men, carotid intima-media thickness and distensi-
bility and vascular stiffness measured by PWV were
reduced by the vegetarian diet [59]. In our study, pa-
tients with PKU had a significant increase in vascular
stiffness, which was independent of blood pressure or
BMI but associated with the serum CRP. Hermida-
Ameijeiras et al. found a similar increase in PWV (clas-
sical PKU only) in a study of 41 PKU patients (age 6–50
years; mean age 23; 61% overweight, 39% obese) who
had no significant changes in blood pressure, heart rate
and blood lipid levels [11]. In their study, PWV was as-
sociated with several other variables including age, BMI,
central diastolic blood pressure, and median Phe plasma
concentrations; however, significant predictors of PWV
in a multivariate analysis were age and central blood
pressure. In another study Htun et al. found an increase
in carotid intima media thickness and local vascular
stiffness [60], which is in accordance with our results.
Taken together, these data indicate endothelial dys-
function and premature vascular ageing in PKU patients.
Increased oxidative stress and a decrease in antioxidative
activity has been demonstrated in PKU patients [53],
which along with the presence of inflammation might
promote vascular damage. Although we could not
find a significant association of PWV with oxidative
stress, it should be noted that our observations were
not targeted to comprehensively analyze oxidative
stress or inflammation but were limited to few se-
lected makers. Further limitations include the small
number of patients and the lack of additional studies
of validated surrogate markers for cardiovascular dis-
ease, such as echocardiography or measurement of in-
tima-media thickness, which could not be performed
in this study for logistical reasons.
In summary, this study provides evidence for an in-
creased cardiovascular risk in PKU patients. An accumu-
lation of traditional cardiovascular risk factors, high
inflammatory and oxidative stress markers, endothelial
dysfunction and vascular stiffness characterize the car-
diovascular phenotype of adult PKU patients. These
findings indicate the need for cardiovascular monitoring
and early preventive measures against cardiovascular dis-
ease in patients with PKU.
Recent guidelines by the American Heart Association
provide detailed recommendations for risk calculation
and treatment of atherosclerotic cardiovascular disease
(ASCVD) for the general population [61]. For adult PKU
patients, we therefore suggest to consider calculating the
individual risk by ASCVD-calculator and to follow the
primary prevention concept of the 2018 AHA recom-
mendation. A statin therapy should be considered in pa-
tients with PKU with an estimated ASCVD risk higher
than 5%.
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